NewAms­ter­dam's bid to re­vive Am­gen car­dio drug heads to Nas­daq in Fra­zier SPAC deal

Five years af­ter Am­gen buried its CETP cho­les­terol drug, a Dutch biotech with hun­dreds of mil­lions in fund­ing is head­ed to Wall Street to con­tin­ue test­ing the ther­a­py in Phase III tri­als.

A month af­ter spread­ing the news about se­cur­ing $123 mil­lion up­front in an over­all €1 bil­lion deal, NewAms­ter­dam Phar­ma is back with more fi­nanc­ing, this time from in­dus­try VC heavy­weights Fra­zier and Bain in a deal that will take the biotech pub­lic via Fra­zier’s blank check com­pa­ny. The SPAC tie-up, which in­cludes a PIPE, will boost NewAms­ter­dam’s cof­fers by $235 mil­lion, round­ing out the com­pa­ny’s to­tal cash re­serves to $470 mil­lion, the com­pa­nies said Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER